This inventor holds 1 USPTO granted patent. Top assignees: Hiroshima University, Japan Science and Technology Agency, Two Cells Co., Ltd.. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2011
Title: Innovations of Nobue Hiromoto in Antifungal Peptides
Introduction
Nobue Hiromoto is an accomplished inventor based in Hiroshima, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of peptides that inhibit fungal growth. His work aims to provide effective treatments for patients with impaired organ function, ensuring safety and efficacy.
Latest Patents
Hiromoto holds a patent for "Peptides and compositions for inhibiting fungal growth." This innovative peptide is designed to exert a higher antifungal effect without side effects. The patent includes several amino acid sequences, such as:
(1) SEQ ID NO:1: Lys-Arg-Leu-Phe-Arg-Arg-Trp-Gln-Trp-Arg-Tyr,
(2) SEQ ID NO:2: Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Tyr,
(3) SEQ ID NO:3: Lys-Arg-Trp-Gln-TTp-Arg-Leu-Tyr,
(4) SEQ ID NO:4: Lys-Arg-Leu-Phe-Lys-Tyr.
The invention encompasses antifungal agents, compositions with fungicidal properties, and medical devices that utilize these peptides.
Career Highlights
Nobue Hiromoto has worked with notable institutions such as the Japan Science and Technology Agency and Hiroshima University. His research has focused on developing innovative solutions to combat fungal infections, contributing to advancements in medical science.
Collaborations
Hiromoto has collaborated with esteemed colleagues, including Hiroki Nikawa and Ryoko Kawabata. Their combined expertise has furthered the research and development of effective antifungal treatments.
Conclusion
Nobue Hiromoto's work in peptide innovation represents a significant advancement in antifungal therapies. His contributions are vital for improving patient outcomes and enhancing the safety of medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile